Latest news with #Securities2025HealthCareConference
Yahoo
07-05-2025
- Business
- Yahoo
Tectonic Therapeutic To Present on May 15th, 2025 at the Bank of America Securities Health Care Conference
Tectonic Therapeutic WATERTOWN, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) ('Tectonic'), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors ('GPCRs'), today announced that Alise Reicin, MD, President and Chief Executive Officer, will present at the Bank of America Securities 2025 Health Care Conference taking place in Las Vegas on May 12-15, 2025. Bank of America Securities Health Care Conference Date: Thursday, May 15th, 2025 Time: 9:20am PDT Format: Corporate Presentation Presenter: Alise Reicin, MD, President and Chief Executive Officer Webcast: Link The Tectonic management team will host one-on-one meetings at the conference. Interested investors should contact their Bank of America Securities representative to schedule meetings. The live webcast can also be accessed under 'Events & Presentations' on the Investors section of the Tectonic website at Once the conference has concluded, a replay of the webcast will be available on the Company's website for approximately 90 days. About Tectonic Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit and follow us on LinkedIn. CONTACT: Investors: Dan Ferry LifeSci Advisors daniel@ (617) 430-7576 Media: Kathryn Morris The Yates Network kathryn@ (914) 204-6412
Business Wire
06-05-2025
- Business
- Business Wire
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2025
CINCINNATI--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:40 PM (PDT) at the Encore at the Wynn Las Vegas. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ( operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations.
Yahoo
06-05-2025
- Business
- Yahoo
Chemed Corporation to Present at the Bank of America Securities Health Care Conference 2025
CINCINNATI, May 06, 2025--(BUSINESS WIRE)--Chemed Corporation (NYSE:CHE) today announced that it will deliver a presentation at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:40 PM (PDT) at the Encore at the Wynn Las Vegas. The presentation will be webcast live and can be accessed, along with the presentation materials, through the Chemed website at (Investor Relations). The webcast replay will be available within 24 hours of the live presentation and will be accessible for 90 days. Listed on the New York Stock Exchange and headquartered in Cincinnati, Ohio, Chemed Corporation ( operates two wholly owned subsidiaries: VITAS Healthcare and Roto-Rooter. VITAS is the nation's largest provider of end-of-life hospice care and Roto-Rooter is the nation's leading provider of plumbing and drain cleaning services. Statements in this press release or in other Chemed communications may relate to future events or Chemed's future performance. Such statements are forward-looking statements and are based on present information Chemed has related to its existing business circumstances. Investors are cautioned that such forward-looking statements are subject to inherent risk that actual results may differ materially from such forward-looking statements. Further, investors are cautioned that Chemed does not assume any obligation to update forward-looking statements based on unanticipated events or changed expectations. View source version on Contacts Michael D. Witzeman (513) 762-6714
Yahoo
06-05-2025
- Business
- Yahoo
Candel Therapeutics to Present at Upcoming Investor Conferences
Candel Therapeutics NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that management will present and participate in one-on-one meetings with investors at upcoming investor conferences. Bank of America Securities 2025 Health Care Conference (Las Vegas, NV) Presenter: Francesca Barone, MD, PhD, Candel's Chief Scientific Officer Date/Time: Wednesday, May 14, 2025, at 4:20 PM PT / 7:20 PM ET Webcast Link: Bank of America / Candel Presentation Jefferies Global Healthcare Conference (New York, NY) Presenter: Paul Peter Tak, MD, PhD, FMedSci, Candel's President and Chief Executive Officer Date/ Time: Thursday, June 5, 2025, at 8:40 AM PT / 11:40 AM ET Webcast Link: Jefferies / Candel Presentation Live webcasts of the presentations will be available by selecting Events and Presentations under the News & Events tab in the Investors section on A replay of the webcasts will be archived for up to 90 days following the session date. About Candel Therapeutics Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 (aglatimagene besadenovec) is the lead product candidate from the adenovirus platform and recently completed successful phase 2a clinical trials in non-small cell lung cancer and borderline resectable pancreatic ductal adenocarcinoma, and a pivotal phase 3 clinical trial in localized prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma. Finally, Candel's enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. For more information about Candel, visit: Forward-Looking Statements This press release includes certain disclosures that contain 'forward-looking statements,' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; and expectations regarding the therapeutic benefit of the Company's platforms. The words 'may,' 'will,' 'could,' 'would,' 'should,' 'expect,' 'plan,' 'anticipate,' 'intend,' 'believe,' 'estimate,' 'predict,' 'project,' 'potential,' 'continue,' 'target' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company's programs; that final data from the Company's preclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company's ability to efficiently discover and develop product candidates; the Company's ability to obtain and maintain regulatory approval of product candidates; the Company's ability to maintain its intellectual property; the implementation of the Company's business model, including strategic plans for the Company's business and product candidates; and other risks identified in the Company's filings with the U.S. Securities and Exchange Commission (SEC), including the Company's most recent Annual Report on Form 10-K filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company's views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
Business Wire
29-04-2025
- Business
- Business Wire
Baxter to Present at Bank of America Securities 2025 Health Care Conference
DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025. Joel Grade, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Pacific Time. The live webcast of Baxter's presentation can be accessed at and will be available for replay through Sunday, November 9, 2025. About Baxter Every day, millions of patients, caregivers and healthcare providers rely on Baxter's leading portfolio of diagnostic, critical care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For more than 90 years, we've been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers who make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter's employees worldwide are now building upon the company's rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit and follow us on X, LinkedIn and Facebook.
